BrainFutures Statement on FDA Approval of Prescription Digital Therapeutic Treatment for Illness

Friday, September 15, 2017

BrainFutures, a nonprofit organization focused on advances in the brain health field, praised the Food and Drug Administration’s September 14 announcement that the first mobile medical application was permitted to treat illness. Linda Raines, CEO of BrainFutures, issued the following statement:

The landmark FDA approval of Pear Therapeutics’ reSET® is about more than one company’s product. This is a potential game-changer for the one in five Americans living with mental health and substance use disorders. BrainFutures applauds the team at Pear Therapeutics for their leadership in advancing new options in care and the FDA for recognizing this new innovation. Too often, people with behavioral health disorders don’t have access to the full range of interventions that can help them achieve better outcomes. Evidence-based advances broaden the spectrum of treatment and support options. We were pleased to have Pear Therapeutics and other experts sharing research-to-practice innovations last week at our BrainFutures 2017 conference.

Read our full FDA media statement